Suppr超能文献

相似文献

1
Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells.
Oncoimmunology. 2015 Apr 1;4(7):e1016700. doi: 10.1080/2162402X.2015.1016700. eCollection 2015 Jul.
2
Therapeutic gene modified cell based cancer vaccines.
Gene. 2013 Aug 10;525(2):200-7. doi: 10.1016/j.gene.2013.03.056. Epub 2013 Apr 6.
3
Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
Hum Vaccin Immunother. 2015;11(4):851-69. doi: 10.1080/21645515.2015.1009814.
4
Myeloid derived suppressor cells-An overview of combat strategies to increase immunotherapy efficacy.
Oncoimmunology. 2015 Feb 3;4(1):e954829. doi: 10.4161/21624011.2014.954829. eCollection 2015 Jan.
6
Emerging role of natural products in cancer immunotherapy.
Acta Pharm Sin B. 2022 Mar;12(3):1163-1185. doi: 10.1016/j.apsb.2021.08.020. Epub 2021 Aug 21.
7
NK cell-based therapeutics for lung cancer.
Expert Opin Biol Ther. 2020 Jan;20(1):23-33. doi: 10.1080/14712598.2020.1688298. Epub 2019 Nov 12.
8
Re-thinking the functions of IgA(+) plasma cells.
Gut Microbes. 2014;5(5):652-62. doi: 10.4161/19490976.2014.969977.
9
Immunomodulating and Immunoresistance Properties of Cancer-Initiating Cells: Implications for the Clinical Success of Immunotherapy.
Immunol Invest. 2017 Apr;46(3):221-238. doi: 10.1080/08820139.2017.1280051. Epub 2017 Mar 13.
10
Trial Watch: Therapeutic vaccines in metastatic renal cell carcinoma.
Oncoimmunology. 2015 Mar 19;4(5):e1001236. doi: 10.1080/2162402X.2014.1001236. eCollection 2015 May.

引用本文的文献

2
Development of therapeutic cancer vaccines based on cancer immunity cycle.
Front Med. 2025 Jul 14. doi: 10.1007/s11684-025-1134-6.
3
New horizons in B-cell lymphoma immunotherapy: From immune checkpoints to precision medicine.
Neoplasia. 2025 Jun 30;67:101206. doi: 10.1016/j.neo.2025.101206.
5
Intrinsic immunosuppressive features of monocytes suppress CAR-T19 through IL-1 pathway modulation in mantle cell lymphoma.
Mol Ther Oncol. 2025 Apr 19;33(2):200985. doi: 10.1016/j.omton.2025.200985. eCollection 2025 Jun 18.
6
Macrophages in prostate cancer: dual roles in tumor progression and immune evasion.
J Transl Med. 2025 Jun 2;23(1):615. doi: 10.1186/s12967-025-06519-x.
7
Advances in CAR optimization strategies based on CD28.
Front Immunol. 2025 Mar 13;16:1548772. doi: 10.3389/fimmu.2025.1548772. eCollection 2025.
8
A myeloid IFN gamma response gene signature correlates with cancer prognosis.
Clin Transl Med. 2025 Apr;15(4):e70139. doi: 10.1002/ctm2.70139.
9
Recent advances in the role of high-salt diet in anti- and pro-cancer progression.
Front Immunol. 2025 Jan 29;16:1542157. doi: 10.3389/fimmu.2025.1542157. eCollection 2025.
10
Role of the TME in immune checkpoint blockade resistance of non-small cell lung cancer.
Cancer Drug Resist. 2024 Dec 16;7:52. doi: 10.20517/cdr.2024.166. eCollection 2024.

本文引用的文献

1
Human fibrocytic myeloid-derived suppressor cells express IDO and promote tolerance via Treg-cell expansion.
Eur J Immunol. 2014 Nov;44(11):3307-19. doi: 10.1002/eji.201444522. Epub 2014 Oct 18.
2
Molecular recognition of gangliosides and their potential for cancer immunotherapies.
Front Immunol. 2014 Jul 21;5:325. doi: 10.3389/fimmu.2014.00325. eCollection 2014.
3
Vascular cell adhesion molecule-1 (VCAM-1)--an increasing insight into its role in tumorigenicity and metastasis.
Int J Cancer. 2015 Jun 1;136(11):2504-14. doi: 10.1002/ijc.28927. Epub 2014 May 6.
4
Molecular Bases for the Regulation of NKG2D Ligands in Cancer.
Front Immunol. 2014 Mar 21;5:106. doi: 10.3389/fimmu.2014.00106. eCollection 2014.
5
Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy.
Cancer Immunol Immunother. 2014 Jun;63(6):545-57. doi: 10.1007/s00262-014-1537-8.
6
B7-H4 as a potential target for immunotherapy for gynecologic cancers: a closer look.
Gynecol Oncol. 2014 Jul;134(1):181-189. doi: 10.1016/j.ygyno.2014.03.553. Epub 2014 Mar 20.
7
CD90(+)CD45(-) intraperitoneal mesothelial-like cells inhibit T cell activation by production of arginase I.
Cell Immunol. 2014 Mar-Apr;288(1-2):8-14. doi: 10.1016/j.cellimm.2014.01.008. Epub 2014 Feb 1.
8
The inflammatory chemokine CCL5 and cancer progression.
Mediators Inflamm. 2014;2014:292376. doi: 10.1155/2014/292376. Epub 2014 Jan 2.
9
New prospects on the NKG2D/NKG2DL system for oncology.
Oncoimmunology. 2013 Oct 1;2(10):e26097. doi: 10.4161/onci.26097. Epub 2013 Oct 25.
10
Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy.
FEBS Lett. 2014 Jan 21;588(2):288-97. doi: 10.1016/j.febslet.2013.11.030. Epub 2013 Dec 1.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验